SCHEMBL7358682

SCHEMBL7358682

Cc1ccc(S(=O)(=O)OC2CCNCC2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 3/20 0.58
HTR6 P50406 7/20 0.52
CYP1A2 P05177 1/20 0.49
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2C19 P33261 1/20 0.41
GAA P10253 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ACHE P22303 1/20 0.38
ALDH1A1 P00352 1/20 0.38
TSHR P16473 1/20 0.38
ENPP3 O14638 1/20 0.37
ENPP1 P22413 1/20 0.37
ENPP2 Q13822 1/20 0.37
VDR P11473 1/20 0.37
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA3 P07451 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL15904173 0.98 CYP2D6 (0.57) CYP2D6HTR6CYP1A2KMT2AMEN1
SCHEMBL3587080 0.90 CYP2D6 (0.52) CYP2D6HTR6CYP1A2KMT2AMEN1
SCHEMBL3587507 0.90 CYP2D6 (0.52) CYP2D6HTR6CYP1A2KMT2AMEN1
SCHEMBL3639846 0.90 CYP2D6 (0.52) CYP2D6HTR6CYP1A2KMT2AMEN1
Hydrochloric Acid SCHEMBL7462759 0.89 CYP2D6 (0.51) CYP2D6HTR6CYP1A2KMT2AMEN1
Trifluoroacetic Acid SCHEMBL22590158 0.88 CYP2D6 (0.51) CYP2D6HTR6CYP1A2KMT2AMEN1
Tert-Butyl Formate SCHEMBL28937843 0.88 CYP2D6 (0.48) CYP2D6HTR6CYP1A2KMT2AMEN1
SCHEMBL10376015 0.88 CYP2D6 (0.67) CYP2D6HTR6CYP1A2KMT2ACYP3A4
SCHEMBL657896 0.88 CYP2D6 (0.67) CYP2D6HTR6CYP1A2KMT2ACYP3A4
SCHEMBL6198029 0.84 CYP2D6 (0.63) CYP2D6HTR6CYP1A2KMT2ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4499628-A1 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERIVATIVES AS DEGRONS IN PROTACS GlaxoSmithKline Intellectual Property Development Limited (GB) 2025-02-05 EP disclosed
WO-2023226950-A1 PEPTIDOMIMETIC STAT PROTEIN DEGRADER, COMPOSITION AND USE THEREOF 杭州和正医药有限公司 2023-11-30 WO disclosed
CN-117126231-A Peptoid STAT protein degradation agent, composition and application thereof 杭州和正医药有限公司 2023-11-28 CN disclosed
WO-2023180388-A1 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERIVATIVES AS DEGRONS IN PROTACS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-09-28 WO disclosed
CN-115448877-A Fused ring pyridone derivative and application thereof 杭州百诚医药科技股份有限公司 2022-12-09 CN disclosed
CN-110312717-B Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and uses thereof 上海瑛派药业有限公司 2022-04-12 CN disclosed
EP-3642195-A1 SUBSTITUTED 5-CYANOINDOLE COMPOUNDS AND USES THEREOF Novartis AG (CH) 2020-04-29 EP disclosed
CN-111032641-A Substituted 5-cyanoindole compounds and uses thereof 诺华股份有限公司 2020-04-17 CN disclosed
US-10604502-B2 Substituted 5-cyanoindole compounds and uses thereof NOVARTIS AG (CH) 2020-03-31 US disclosed
US-20190023684-A1 SUBSTITUTED 5-CYANOINDOLE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2019-01-24 US disclosed
WO-2014116070-A1 METHOD FOR PREPARING 1-(4-(4-(3,4-DICHLORO-2-FLUOROPHENYLAMINO)-7-METHOXYQUINAZOLIN-6-YLOXY)PIPERIDIN-1-YL)PROP-2-EN-1-ONE HANMI PHARM. CO., LTD. (KR) 2014-07-31 WO disclosed
WO-2013071697-A1 AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2013-05-23 WO disclosed
WO-2011143163-A1 SUBSTITUTED N-PHENYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2011-11-17 WO disclosed
EP-2202223-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-06-30 EP disclosed
WO-2008150848-A1 ANTIDEPRESSANT HETEROARYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS WYETH (US) 2008-12-11 WO disclosed
CN-1058262-C Novel 1-phenylalkanone 5-HT4Receptor ligands SYNTEX INC (US) 2000-11-08 CN disclosed
EP-0700383-B1 NOVEL 1-PHENYLALKANONE 5-HT 4? RECEPTOR LIGANDS SYNTEX INC (US) 1998-09-23 EP disclosed
US-5763458-A NERVOUS SYSTEM DISORDERS, ANXIETY, ANTIDEPRESSANTS AND COGNITION ACTIVATORS SYNTEX (U.S.A.) INC. (US) 1998-06-09 US disclosed
CN-1124485-A Novel 1-phenylalkanone 5-HT4Receptor ligands SYNTEX A INC (US) 1996-06-12 CN disclosed
WO-1994027965-A1 NOVEL 1-PHENYLALKANONE 5-HT4 RECEPTOR LIGANDS SYNTEX (U.S.A.) INC. (US) 1994-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10604502-B2 Substituted 5-cyanoindole compounds and uses thereof KDM1A, KDM5A, KDM1B CYP2D6 1183/4885HTR6 1102/4885CYP1A2 274/4885
US-20190023684-A1 SUBSTITUTED 5-CYANOINDOLE COMPOUNDS AND USES THEREOF KDM1A, KDM5A, KDM1B CYP2D6 1183/4885HTR6 1102/4885CYP1A2 274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.